{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:46:44Z","timestamp":1790858804640,"version":"4.1.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Rate control of atrial fibrillation (AF) in acute heart failure (AHF) with reduced left ventricular ejection fraction (LVEF) is challenging. We evaluated the safety and efficacy of intensive rate control (IRC) using landiolol with adjunctive digoxin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Forty patients with AHF due to AF [heart rate (HR) &amp;gt; 130\/min, LVEF &amp;lt;40%] were randomized to IRC with landiolol plus digoxin or standard rate control therapy. The primary endpoint was sustained HR reduction &amp;gt;20% or &amp;lt;115\/min at 2\u2005h. Haemodynamics, dyspnoea, and lung congestion were assessed serially. HR control was achieved faster in the IRC vs. standard group (median 1.5 vs. 4\u2005h; P = 0.016). At 2\u2005h, HR decreased by 40% of the IRC group vs. 23% of standard therapy group (P = 0.045), and the primary endpoint was reached in 80% vs. 20% of the patients, respectively (P = 0.04). IRC resulted in greater dyspnoea relief and lung decongestion without excess hypotension or adverse events. At 24\u2005h, outcomes between the groups were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In AHF with reduced LVEF, protocolized landiolol-based intensive rate control provides faster and safe HR reduction with early symptomatic benefit compared with standard therapy.<\/jats:p>\n                    <jats:p>Pre-registered Clinical Trial Number: \u00a0ClinicalTrials.org: NCT04694092.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuag027","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:43:42Z","timestamp":1772109822000},"page":"622-626","source":"Crossref","is-referenced-by-count":2,"title":["Landiolol for rate control in decompensated heart failure due to atrial fibrillation: the LARISA trial"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-0086","authenticated-orcid":false,"given":"Marek","family":"Sramko","sequence":"first","affiliation":[{"name":"Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM) , Videnska 1958\/9, Prague 14021 ,","place":["Czech Republic"]},{"name":"2nd Department of Cardiology and Angiology, General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Benak","sequence":"additional","affiliation":[{"name":"Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM) , Videnska 1958\/9, Prague 14021 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Toman","sequence":"additional","affiliation":[{"name":"Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM) , Videnska 1958\/9, Prague 14021 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kleissner","sequence":"additional","affiliation":[{"name":"Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM) , Videnska 1958\/9, Prague 14021 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pazdernik","sequence":"additional","affiliation":[{"name":"Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM) , Videnska 1958\/9, Prague 14021 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-6182","authenticated-orcid":false,"given":"Josef","family":"Kautzner","sequence":"additional","affiliation":[{"name":"Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM) , Videnska 1958\/9, Prague 14021 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026082907321251400_zuag027-B1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082907321251400_zuag027-B2","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026082907321251400_zuag027-B3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF03016588","article-title":"In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol","volume":"48","author":"Sasao","year":"2001","journal-title":"Can J Anaesth"},{"key":"2026082907321251400_zuag027-B4","first-page":"95","article-title":"A multicentre observational study on landiolol use, efficacy, and safety in European patients with supraventricular arrhythmia (landi-UP)","volume":"15","author":"Dizdarevic","year":"2026","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026082907321251400_zuag027-B5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082907321251400_zuag027-B6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter ablation in End-stage heart failure with atrial fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082907321251400_zuag027-B7","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1253\/circj.CJ-18-1361","article-title":"Efficacy and safety of the ultra-short-acting \u03b21-selective blocker landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhymias- outcomes of J-land II study","volume":"83","author":"Ikeda","year":"2019","journal-title":"Circ J"},{"key":"2026082907321251400_zuag027-B8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jjcc.2019.05.012","article-title":"A prospective observational survey on landiolol in atrial fibrillation\/atrial flutter patients with chronic heart failure\u2014AF-CHF landiolol survey","volume":"74","author":"Yamashita","year":"2019","journal-title":"J Cardiol"}],"container-title":["European Heart Journal: Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuag027\/67169774\/zuag027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/8\/622\/67169774\/zuag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/8\/622\/67169774\/zuag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:32:19Z","timestamp":1788003139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/15\/8\/622\/8502044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":8,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuag027","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,2,27]]}}}